Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Adriaan, Cleton"'
Autor:
Selina K. Wong, Quincy S.C. Chu, Jennifer L. Spratlin, Randeep Sangha, Alexander J.B. McEwan, Donald W. Morrish, Diane Arndt, Gwen Sergenson, Adriaan Cleton, Funan Huang, Michael B. Sawyer
Publikováno v:
Case Reports in Oncology, Vol 12, Iss 3, Pp 791-795 (2019)
Thyroid cancer is the most common type of endocrine malignancy. Cornerstones of thyroid cancer treatment include surgery, radioactive iodine ablation, and thyroid stimulating hormone suppression. The National Comprehensive Cancer Network guidelines r
Externí odkaz:
https://doaj.org/article/17f84ca3eeef446c9c88b10e69478f3b
Autor:
Lynley V. Marshall, Irene Jiménez, Andrew D.J. Pearson, Udo Mueller, Adriaan Cleton, Bart Ploeger, Michael Teufel, Patricia Maeda, Sarah Schlief, Bruce Morland, Andrea C. Agostinho, Gilles Vassal, Jasmine Kincaide, Birgit Geoerger, Didier Frappaz
Publikováno v:
European Journal of Cancer. 153:142-152
Background This phase 1 study evaluated safety, pharmacokinetics (PK), maximum tolerated dose (MTD), and antitumour activity of regorafenib in paediatric patients with solid tumours. Patients and methods Patients (aged 6 months to Results Forty-one p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6ce50d56d650acd3c02420f1172c518
https://doi.org/10.1016/j.ejca.2021.05.023
https://doi.org/10.1016/j.ejca.2021.05.023
Autor:
Xue-Ning Li, Jinyi Li, Chao Liu, Adriaan Cleton, Yubin Sui, Hong-Rong Xu, Lei Sheng, Fei Yuan, Yuwang Liu
Publikováno v:
Clinical Pharmacology in Drug Development. 11:173-184
Acarbose and metformin have been recommended both as monotherapy and add-on therapy in type 2 diabetes mellitus. A novel fixed-dose combination (FDC) of acarbose and metformin has been developed to improve compliance and patient adherence to therapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8057ee957fbf6302b6e190e4750511c0
https://doi.org/10.1002/cpdd.994
https://doi.org/10.1002/cpdd.994
Publikováno v:
Cancer Biotherapy & Radiopharmaceuticals
Introduction: Thorium-227 is an alpha-emitting radioisotope with potential therapeutic applications in targeted alpha therapy. Thorium-227 decays to Radium-223, which may have an independent biodistribution to that of the parent Thorium-227 radiophar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68f35d16d5a2c4b16c7856a6c0c14624
http://europepmc.org/articles/PMC7475104
http://europepmc.org/articles/PMC7475104
Publikováno v:
British Journal of Clinical Pharmacology
Aim Regorafenib is an oral multikinase inhibitor with clinical efficacy in a range of advanced solid tumours. A population pharmacokinetic (PK) model was developed to evaluate the variability of the PK of regorafenib and its pharmacologically active
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d2103c08b9cb0ccb6c1b0f624bdf288
https://doi.org/10.1111/bcp.14334
https://doi.org/10.1111/bcp.14334
Autor:
George Sgouros, Shalini Subramanian, Adriaan Cleton, Wesley E. Bolch, Eric C. Frey, Derek W. Jokisch, Hartwig Hennekes, Bin He, Sandra Johanssen, Thorsten Poethko
BackgroundIn 2016, the International Commission on Radiological Protection and Measurements (ICRP), published the results of Monte Carlo simulations performed using updated and anatomically realistic voxelized phantoms. The resulting absorbed fractio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d30a83d2130f8f1301c68bde40198e0e
https://doi.org/10.21203/rs.3.rs-320927/v1
https://doi.org/10.21203/rs.3.rs-320927/v1
Publikováno v:
Cancer biotherapyradiopharmaceuticals. 35(7)
Thorium-227 (227Th) is a long-lived (T1/2 = 18.7 d) α-emitter that has emerged as candidate for radioimmunotherapy. Imaging of patients treated with thorium-227 conjugates is challenging due to the...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a22f1b1db8ba3cb0cce4e5d99a7f893c
https://pubmed.ncbi.nlm.nih.gov/32486837
https://pubmed.ncbi.nlm.nih.gov/32486837
Autor:
Konstanze Diefenbach, Michael Gerisch, Dieter Lang, Martin Radtke, Frank-Thorsten Hafner, John Lettieri, Adriaan Cleton
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose To evaluate the mass balance, metabolic disposition, and pharmacokinetics of a single dose of regorafenib in healthy volunteers. In addition, in vitro metabolism of regorafenib in human hepatocytes was investigated. Methods Four healthy male
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea118d9d9935d6ba0621d1b197c73418
https://doi.org/10.1007/s00280-017-3480-9
https://doi.org/10.1007/s00280-017-3480-9
Autor:
Jordi Bruix, Adriaan Cleton, Alexander Solms, Anne Keunecke, Isabel Reinecke, Bart Ploeger, Gerold Meinhardt, Henk-Jan Drenth, Sabine Fiala-Buskies
Publikováno v:
European Journal of Pharmaceutical Sciences. 109:S149-S153
To explore the relationship between regorafenib exposure and efficacy in patients with hepatocellular carcinoma (HCC) who had disease progression during sorafenib treatment (RESORCE).Exposure-response (ER) analyses for regorafenib were performed usin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee6de012834797411d2dc15a65043b82
https://doi.org/10.1016/j.ejps.2017.05.050
https://doi.org/10.1016/j.ejps.2017.05.050
Autor:
Johanna Melin, Adriaan Cleton, Susanne Prothon, Ulrika Wählby Hamrén, Per Bäckman, Carl Amilon, Bo Olsson, Charlotte Kloft, Carin Jorup
Publikováno v:
The AAPS Journal. 19:865-874
AZD5423 is a non-steroidal glucocorticoid receptor modulator, with low aqueous solubility, developed for treatment of asthma and COPD. In this work, we aim to evaluate and compare the absorption pharmacokinetics (PK) of AZD5423 after inhalation via f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bef2a673b15ab55bbe7e9df92558fe65
https://doi.org/10.1208/s12248-016-0042-8
https://doi.org/10.1208/s12248-016-0042-8